Acquisition by Craig Swandal of 17000 shares of Apyx Medical subject to Rule 16b-3
| APYX Stock | USD 1.61 0.08 4.73% |
Slightly above 61% of Apyx Medical's investor base is looking to short. The analysis of overall sentiment of trading Apyx Medical stock suggests that many investors are alarmed at this time. Apyx Medical's investing sentiment can be driven by a variety of factors including economic data, Apyx Medical's earnings reports, geopolitical events, and overall market trends.
Apyx |
Filed transaction by Apyx Medical Corp director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Apyx Medical Fundamental Analysis
We analyze Apyx Medical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Apyx Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Apyx Medical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
Apyx Medical is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Apyx Medical Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Apyx Medical stock to make a market-neutral strategy. Peer analysis of Apyx Medical could also be used in its relative valuation, which is a method of valuing Apyx Medical by comparing valuation metrics with similar companies.
Peers
Apyx Medical Related Equities
| NPCE | Neuropace | 3.41 | ||||
| ANIK | Anika Therapeutics | 3.02 | ||||
| LUNG | Pulmonx Corp | 2.38 | ||||
| KIDS | Orthopediatrics Corp | 2.32 | ||||
| OFIX | Orthofix Medical | 2.09 | ||||
| SGHT | Sight Sciences | 2.05 | ||||
| AORT | Artivion | 1.62 | ||||
| INGN | Inogen | 0.83 | ||||
| AVNS | Avanos Medical | 0.10 | ||||
| LIVN | LivaNova PLC | 0.04 | ||||
| SRDX | SurModics | 0.23 | ||||
| ELMD | Electromed | 0.90 | ||||
| AXGN | Axogen | 1.21 |
Additional Tools for Apyx Stock Analysis
When running Apyx Medical's price analysis, check to measure Apyx Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apyx Medical is operating at the current time. Most of Apyx Medical's value examination focuses on studying past and present price action to predict the probability of Apyx Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apyx Medical's price. Additionally, you may evaluate how the addition of Apyx Medical to your portfolios can decrease your overall portfolio volatility.